The global urinary tract infection market is anticipated to grow at a CAGR of 4.8% during the forecast period (2024-2031). The key factor to drive the market growth is the increasing prevalence of diabetes and obesity due to the adoption of unhealthy lifestyles and increasing addiction to alcohol and obesity in many countries. For instance, according to International Diabetes Association in 2019, Diabetes affects approximately 463 million people aged 20 to 79, with the number expected to increase to 700 million by 2045. Diabetes cost the US economy at least $760 billion in 2019, accounting for 10% of total adult spending. Further, Adult obesity rates now exceed 35% in 12 states, 30% in 35 states, and 25% in 48 states, according to the most recent Behavioural Risk Factor Surveillance System (BRFSS) data. Mississippi has the highest adult obesity rate (40.8%), while Colorado and Washington, DC have the lowest (23.8%). Between the years 2018 and 2019,
Get Free Sample link @ https://www.omrglobal.com/request-sample/urinary-tract-infection-treatment-market
Rising acquisitions, product approval, collaborations among the major players if the market also propel the growth of the market. For instance, in July 2019, Recarbrioan antibacterial drug product has been approved by the US Food and Drug Administration (FDA) to treat adults with complicated urinary tract infections and complicated intra-abdominal infections. With this approval The FDA is committed to encouraging the production of new antibacterial drugs that are both safe and reliable, giving patients more choices in the battle against severe infections.
Full report of Urinary Tract Infection Market available @ https://www.omrglobal.com/industry-reports/urinary-tract-infection-treatment-market
Market Coverage
- Segment Covered-
o By Test Type
o By Indication
o By End-User
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- AstraZeneca PLC, Bayer AG, Danaher Corp., Becton, Dickinson and Co., Biotronik SE & Co. KG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Pfizer Inc., Siemens AG, and others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Urinary Tract Infection Market Report Segment
BY Test Type
- Biochemical Urinary Tract Infection
- Microscopic Urinary Tract Infection
- Flow Cytometric Urinary Tract Infection
BY Indication
- Complicated Urinary Tract Infection
- Uncomplicated Urinary Tract Infection
- Neurogenic Bladder Infections
By End-User
- Hospitals and Clinics
- Home Healthcare
Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/urinary-tract-infection-treatment-market
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
